Hints and tips:
...A 56-page report from lawmakers who spearheaded the investigation described several eyebrow-raising expenditures, including his use of campaign funds to pay for Botox....
...His expenditures, it said, included using campaign funds to pay for Botox — and a limited liability company linked to the campaign transferred tens of thousands of dollars to the congressman’s personal accounts...
...Kuvings REVO830 cold press juicer, £549, ukjuicers.com RM The Botox alternative At-home devices such as the GloPRO Microneedling Regeneration Tool by Beauty Bio create controlled micro-trauma to the skin...
...The deal is the largest pharmaceutical transaction since AbbVie agreed to buy Allergan for $63bn in 2019 and signals a rebound in mergers and acquisitions following a dip in activity last year, according...
...I posit that perhaps Hästens’ customers can afford Botox. Ryde’s approach to leadership has at times been controversial....
...The posh OC has had its share of corporate battles over the years: Bill Ackman’s 2015 brawl with Botox maker Allergan; a 2013 boardroom scrap between Emulux and Elliott Management; and Broadcom’s 2018 fight...
...US drugmaker AbbVie’s $63bn deal to buy Allergan, the Irish-domiciled maker of Botox, required a second request for information from the FTC and received a narrow 3-2 vote for approval by commissioners last...
...As well as Botox, Allergan makes drugs that are used in eyecare, gastroenterology and to treat the central nervous system....
...A subsequent attempt to slash its tax bill by acquiring Allergan, the Botox maker, and moving its headquarters to Ireland was nixed by the Obama administration....
...The acquisition is the biggest transaction in pharmaceuticals since 2019, when AbbVie acquired Allergan for $63bn, and the largest deal to target a US company in any sector this year....
...On Tuesday, pharma giant AbbVie announced that it was acquiring Allergan, best known as the maker of Botox, at an enterprise value of $85bn....
...With Allergan, AbbVie will add Botox as well as a host of drugs that are used in eyecare, gastroenterology and to treat the central nervous system to its portfolio....
...JPMorgan Chase is poised to collect the largest individual fee to a bank for selling a company, earning $123m for advising Botox-maker Allergan on a planned $63bn sale to US pharmaceutical group AbbVie....
...US drugmaker AbbVie has agreed to buy Allergan, the Irish-domiciled maker of Botox, in a $63bn deal that is the sector’s latest blockbuster transaction driven by the need to replenish drug pipelines....
...Abbvie’s $63bn deal to acquire Allergan, the maker of Botox, is also part of a plan to bolster the company’s pipeline of new drugs before it loses exclusivity on Humira in the US in 2023, when it expects...
...Since then, Allergan — best known for its cosmetic drug Botox — has been struggling to keep pace with Wall Street’s thirst for growth....
...Allergan raised expectations for the full year after the pharmaceutical company best known for its cosmetic products beat analysts' forecasts on earnings and revenue, driven by rising sales of Botox and...
...(FT, Bellingcat) Pharma deal cleared The Federal Trade Commission has given the go-ahead for US drugmaker AbbVie’s $63bn takeover of Botox-maker Allergan, which will see some of the latter’s assets sold...
...Another deal that Lex had doubts about was the AbbVie-Allergan pharma deal. Allergan, the maker of Botox and once a Wall Street darling, has more than a few wrinkles in its business to smooth out....
...Allergan, best known for its popular wrinkle treatment Botox, has been under pressure by Appaloosa to take “radical remediation measures” to improve its performance....
...Appaloosa, David Tepper’s hedge fund, is urging Botox maker Allergan to take “radical remediation measures” to improve the drugmaker’s performance and again urged it to split the chairman and chief executive...
...Fed chairman Jay Powell warns that risks to global growth have increased in recent weeks, AbbVie investors give the US drugmaker a resounding thumbs down on its bid to buy Botox-maker Allergan and FedEx...
...For JPMorgan Chase, which advised Botox-maker Allergan on its $63bn sale to US pharmaceutical group AbbVie, the “miracle” drug has instead been closer to a shot in the heart....
...Tuesday 13:30 BST What’s happening ● Allergan jumped to its highest level since October after AbbVie agreed to buy the Botox maker for $63bn or $188 a share, a 45 per cent premium to Monday’s closing price...
...Plus, the FT’s corporate finance and deals editor, Arash Massoudi, explains what led to AbbVie’s $63bn acquisition of Botox-maker Allergan....
International Edition